This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • Neurology  • Cerebrovascular Disease  • Stroke  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Cabral states that our results "contradict" our previous report showing a "high risk of stroke." Our prior report¹ was a case-control study of first stroke in patients with aCL. Our current study looked at both LA and aCL in predicting recurrent thrombo-occlusive events—these are different questions, different populations, and different methodologies and, hence, not contradictory. We did not intend to suggest that our results are applicable to all populations at risk for, or that have experienced, stroke. As with most studies, our results are most generalizable to patients similar to those eligible for inclusion. Few young patients with stroke and established APS were included. Our report, however, provides the largest randomized trial to date to evaluate the significance of aPL status for recurrent stroke and the efficacy of warfarin. Given that the vast majority of ischemic strokes are not from APS but rather have etiologies more representative . . . [Full Text of this Article]

Steven R. Levine, MD
steven.levine@mssm.edu

Robin L. Brey, MD; Barbara C. Tilley, PhD; Douglas A. Triplett, MD; J. L. P. Thompson, PhD; Ralph L. Sacco, MD; J. P. Mohr, MD for the APASS Investigators

RELATED ARTICLES

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Antonio R. Cabral
JAMA. 2004;291(22):2701.
EXTRACT | FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Guillermo Ruiz-Irastorza, Munther A. Khamashta, and Graham R. V. Hughes
JAMA. 2004;291(22):2701.
EXTRACT | FULL TEXT  

Antiphospholipid Antibodies and Risk for Recurrent Vascular Events
Denis Wahl, Véronique Regnault, Philippe de Moerloose, and Thomas Lecompte
JAMA. 2004;291(22):2701-2702.
EXTRACT | FULL TEXT  

Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients With Ischemic Stroke
APASS Investigators
JAMA. 2004;291(5):576-584.
ABSTRACT | FULL TEXT